Integrated Biopharma (Integrated Biopharma) GF Value : $0.46 (As of May. 10, 2024)

View and export this data going back to 1996. Start your Free Trial

What is Integrated Biopharma GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-10), Integrated Biopharma's share price is $0.2182. Integrated Biopharma's GF Value is $0.46. Therefore, Integrated Biopharma's Price-to-GF-Value for today is 0.47.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Integrated Biopharma is Possible Value Trap, Think Twice.

Integrated Biopharma (OTCPK:INBP) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Integrated Biopharma's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	0.2182	/	0.46
	=	0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Integrated Biopharma GF Value Related Terms

Thank you for viewing the detailed overview of Integrated Biopharma's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Integrated Biopharma (Integrated Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Integrated Biopharma Inc (OTCPK:INBP) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

225 Long Avenue, Building 15, Hillside, NJ, USA, 07205

Website

http://www.ibiopharma.com

Integrated Biopharma Inc is a pharmaceutical company engaged in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. It operates in two segments; Contract Manufacturing and Other Nutraceutical Businesses. It serves the needs of the nutraceutical industry by directly doing business as Chem International Inc. and through its operating subsidiaries; Manhattan Drug Company, Inc., AgroLabs, Inc., IHT Health Products, Inc. and MDC Warehousing and Distribution, Inc. The company generates maximum revenue from the Contract Manufacturing segment. The business operates and generates the majority of revenue from the United States.

Executives

Damon Desantis	director	2424 N FEDERAL HIGHWAY, SUITE 208, BOCA RATON FL 33431
William H. Milmoe	director, 10 percent owner	3299 N.W. 2ND AVENUE, BOCA RATON FL 33431
Joseph Laplaca	director	72 EUGENE DRIVE, MONTVILLE NJ 07045
E Gerald Kay	director, 10 percent owner, officer: Chairman and CEO	C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Bradley J Hoecker	director	STONINGTON PARTNERS, INC., 540 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Jeffrey R Leach	director, officer: President and CEO
Glenn Chang	director	C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Vidadi Yusibov	director	C/O IBIOPHARMA, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Cd Financial, Llc	10 percent owner	3299 N.W. 2ND AVENUE, BOCA RATON FL 33431
Kay Riva	director, officer: Vice President	C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Christina Kay	director, officer: Vive President	C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Robert Canarick	director	C/O INTEGRATED BIOPHARMA, INC., 201 ROUTE 22, HILLSIDE NJ 07205
Robert Kay	director	C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Dina Masi	officer: Chief Financial Officer	14 LEXINGTON WAY, LONG VALLEY NJ 07853
Carl Desantis	director, 10 percent owner	C/O CDS INTERNATIONAL HOLDINGS, 3299 NW SECOND AVE, BOCA RATON FL 33431